Skip to main content

Table 1 Patient demographics at baseline (week 0, safety analysis set and per protocol analysis set)

From: Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial

  Safety set Per protocol set
  Lanthanum carbonate Placebo Lanthanum carbonate Placebo
(n = 23) (n = 12) (n = 17) (n = 12)
Age, years     
  Mean (SD) 66.0 (13.9) 69.4 (13.2) 65.6 (14.7) 69.4 (13.2)
  Median 65.0 72.5 65 73
  Range 38–84 43–87 38–84 43–87
Gender, n (%)     
  Male 13 (56.5) 5 (41.7) 10 (58.8) 5 (41.7)
Ethnicity, n (%)     
  White 16 (69.6) 9 (75) 12 (70.6) 9 (75.0)
  Black 6 (26.1) 2 (16.7) 5 (29.4) 2 (16.7)
  Asian 0 (0.0) 1 (8.3) 0 (0.0) 1 (8.3)
Body mass index, kg/m2, mean (SD) 29.9 (5.1) 30.1 (5.1) 29.4 (4.9) 30.1 (5.1)
iGFR (ml/min/1.73 m2), mean (SD) 42.5 (10.7) 48.0 (13.1) 42.2 (10.1) 48.0 (13.1)
  1. iGFR, iohexol glomerular filtration rate; SD, standard deviation.
\